Eloxx Phase 2 ELX-02 monotherapy shows 5.4 mmol/L sweat chloride reduction; advancing to Phase 3

Eloxx Pharmaceuticals, Inc.

Statistically significant 5.4 mmol/L mean sweat chloride reduction at 1.5 mg/kg/day (p=0.022) in Class 1 CF patients with G542X mutation.
ELX-02 well tolerated; no treatment-related serious adverse events; most common mild injection site reactions.
Planning for Phase 3 clinical development initiated; 1.5 mg/kg/day dose selected for further study.
First patient dosed in Phase 2 combination arm with ivacaftor; topline data expected by H1 2022.
Evaluation of inhaled delivery of ELX-02 started; IND submission planned for H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.